These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38179713)

  • 1. Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis.
    Chen CH; Liao HT; Chen HA; Yen YN; Chen CH
    Clin Exp Rheumatol; 2024 May; 42(5):1020-1028. PubMed ID: 38179713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.
    Kinoshita H; Miyakoshi N; Kashiwagura T; Kasukawa Y; Sugimura Y; Shimada Y
    Mod Rheumatol; 2017 Jul; 27(4):582-586. PubMed ID: 27659808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.
    Matsuno H
    Drugs R D; 2016 Dec; 16(4):347-353. PubMed ID: 27766589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of serum bone-related minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis: Mineral change by denosumab in osteoporosis with rheumatoid arthritis.
    Suzuki T; Nakamura Y; Kato H
    Clin Nutr ESPEN; 2018 Aug; 26():53-56. PubMed ID: 29908683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population-based retrospective study of 6408 patients.
    Dong C; Chen BS; Wu CH; Chiu YM; Liao PL; Perng WT
    Int J Rheum Dis; 2024 Aug; 27(8):e15286. PubMed ID: 39154356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
    Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting.
    Lau AN; Wong-Pack M; Rodjanapiches R; Ioannidis G; Wade S; Spangler L; Balasubramanian A; Pannacciulli N; Lin CJF; Roy-Gayos P; Bensen WG; Bensen R; Adachi JD
    J Rheumatol; 2018 Feb; 45(2):170-176. PubMed ID: 29142041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study.
    Murata K; Uozumi R; Hashimoto M; Ebina K; Akashi K; Onishi A; Nagai K; Yoshikawa A; Katayama M; Son Y; Amuro H; Hara R; Yamamoto W; Watanabe R; Murakami K; Tanaka M; Ito H; Morinobu A; Matsuda S
    Mod Rheumatol; 2022 Jul; 32(4):834-838. PubMed ID: 34910199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study.
    Kim SK; Kim JW; Lee H; Park SH; Choe JY; Kim B
    Medicine (Baltimore); 2023 Jun; 102(26):e34219. PubMed ID: 37390268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Nasu Y; Okazaki K
    Mod Rheumatol; 2021 May; 31(3):600-606. PubMed ID: 32815449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting.
    Berry SD; Dufour AB; Travison TG; Zhu H; Yehoshua A; Barron R; Recknor C; Samelson EJ
    Arch Osteoporos; 2018 Nov; 13(1):124. PubMed ID: 30421141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
    Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
    Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.